UPSC Medical Science 2023

The directive 'describe' demands comprehensive, structured exposition of anatomical pathways, physiological mechanisms, and biochemical processes. Allocate time proportionally: ~20% for (a)(i)-(ii) lymphatic drainage and swallowing; ~20% for (b)(i)-(ii) auditory pathway and cortical blood supply; ~20% for (c) folic acid biochemistry; ~20% for (d) cerebellar physiology; and ~20% for (e) sleep physiology. Begin each sub-part with a brief contextual statement, present core content with appropriate headings, and conclude with clinical significance where applicable.

• For (a)(i): Flowchart showing submandibular → deep cervical (jugulodigastric/jugulo-omohyoid) → supraclavicular nodes; mention of lymphatic levels I-V for oral cancer staging
• For (a)(ii): Sequential phases of swallowing (oral preparatory, oral, pharyngeal, esophageal) with tongue's propulsive, sensory, and airway protective roles
• For (b)(i)-(ii): Complete auditory pathway (cochlear nerve → cochlear nuclei → superior olivary complex → lateral lemniscus → inferior colliculus → medial geniculate body → Heschl's gyrus); middle cerebral artery (temporal branches) and posterior cerebral artery supply to auditory cortex
• For (c): Dietary sources (green leafy vegetables, lentils, liver); RDA (400 μg adults, 600 μg pregnancy); megaloblastic anemia, neural tube defects, hyperhomocysteinemia; folate trap mechanism (B12 deficiency blocking THF regeneration)
• For (d): Cerebellar coordination via feedforward/feedback mechanisms (comparator function, error correction, motor learning); dysfunction signs (intention tremor, dysmetria, dysdiadochokinesia, nystagmus, ataxia)
• For (e): REM genesis (pons-geniculate-occipital waves, cholinergic activation, monoaminergic inhibition); paradoxical features (EEG desynchronization resembling wakefulness with muscle atonia, vivid dreams, penile erection)

The directive 'describe' demands comprehensive, structured exposition of anatomical, biochemical, and physiological facts. Allocate approximately 30% of time to part (a) prostate anatomy (15 marks), 40% to part (b) biochemistry (20 marks), and 30% to part (c) pregnancy physiology (15 marks). Structure each sub-part with clear headings: for (a) use anatomical zones and relations; for (b) use biochemical pathways and disease mechanisms; for (c) use system-based physiological changes. Include labeled diagrams for prostate relations and cardiovascular changes.

• Part (a)(i): Median lobe enlargement compressing prostatic urethra at the bladder neck; internal sphincter involvement causing obstructive symptoms
• Part (a)(ii): Anterior-pubic symphysis and retropubic space; posterior-rectovesical septum and Denonvilliers' fascia; lateral-levator ani; superior-bladder neck; inferior-urogenital diaphragm and external urethral sphincter
• Part (a)(iii): Arterial supply from inferior vesical, middle rectal, and internal pudendal arteries; venous drainage to prostatic venous plexus → internal iliac veins; lymphatics to internal iliac, sacral, and obturator nodes
• Part (b)(i): Copper as cofactor for cytochrome c oxidase, superoxide dismutase, lysyl oxidase, ceruloplasmin; Wilson disease as ATP7B mutation causing defective copper excretion and ceruloplasmin deficiency; diagnostic tests: serum ceruloplasmin, serum copper, 24-hour urinary copper, hepatic copper concentration, Kayser-Fleischer rings
• Part (b)(ii): Genetic code as triplet, non-overlapping, degenerate, universal, commaless; Wobble hypothesis (Crick) explaining third base degeneracy with anticodon wobble position; post-translational modifications: phosphorylation, glycosylation, ubiquitination, proteolytic cleavage, disulfide bond formation
• Part (c): Genital organs-uterine enlargement, cervical softening, vaginal vascularity; Blood-increased plasma volume, physiological anemia, hypercoagulability; Cardiovascular-increased cardiac output, decreased peripheral resistance, supine hypotension syndrome, hemodilution

The directive 'describe' demands comprehensive, structured exposition with precise anatomical, biochemical and physiological detail. Allocate approximately 40% time/words to part (a) [20 marks], 30% to part (b) [15 marks], and 30% to part (c) [15 marks]. Structure each sub-part with clear headings: for (a) use tabular format for knee movements and separate sections for CTS; for (b) present PCR steps sequentially and list cholestasis markers with clinical significance; for (c) explain Starling's law mechanisms and erythropoietin regulation cascade. Include labeled diagrams for knee joint, carpal tunnel, PCR cycles, and cardiac function curves.

• Knee joint: All six movements (flexion, extension, rotation, locking, unlocking) with muscle pairs; screw-home mechanism and popliteus role; ACL/PCL functions in anteroposterior stability and pivot control
• Carpal Tunnel Syndrome: Median nerve compression at flexor retinaculum; causes (trauma, RA, hypothyroidism, pregnancy, repetitive strain); thenar atrophy, nocturnal paresthesia, Tinel/Phalen signs
• PCR: Principle of DNA amplification via Taq polymerase; three steps (denaturation, annealing, extension) with temperatures; applications in TB diagnosis (CBNAAT), genetic testing, COVID-19 RT-PCR
• Cholestasis markers: Elevated ALP, GGT, 5'-nucleotidase; conjugated hyperbilirubinemia; bile acid elevation; distinguish from hepatocellular injury (AST/ALT pattern)
• Cardiac output regulation: Frank-Starling mechanism (length-tension relationship), heart rate modulation, contractility changes; autonomic and hormonal influences on intrinsic properties
• Erythropoiesis regulation: EPO from peritubular cells, hypoxia-inducible factor (HIF); iron, B12, folate requirements; stages from BFU-E to reticulocyte; feedback via RBC mass

The directive 'describe' demands comprehensive, structured exposition of mechanisms and features across all sub-parts. Allocate approximately 35% of time/words to (b)(i) as it carries 15 marks; 20% each to (a)(i) and (c)(i) at 10 marks each; and 15% combined for the three 5-mark sub-parts (a)(ii), (b)(ii), (c)(ii). Structure as: embryology section → endocrinology section → biochemistry section, with brief introductions and summaries for each major part.

• SRY gene mechanism: SOX9 upregulation, SF1 interaction, testis-specific enhancer (TSE), Sertoli cell differentiation and AMH secretion
• Vitelline duct abnormalities: Meckel's diverticulum (Rule of 2s), vitelline fistula, umbilical sinus, vitelline cyst; embryological basis of persistence
• Iodine in thyroid hormone synthesis: iodide trapping by NIS, organification by TPO, coupling reaction; Hashimoto's as autoimmune destruction with anti-TPO and anti-Tg antibodies, elevated TSH, low T3/T4
• Vitamin K biochemistry: gamma-carboxylation of glutamate residues (GLA domain) in Factors II, VII, IX, X; Warfarin as vitamin K epoxide reductase (VKORC1) inhibitor creating functional deficiency
• Vasopressin (ADH): V2 receptor-mediated water reabsorption in collecting ducts via aquaporin-2 insertion; osmoreceptor (hypothalamic) and volume/pressure (baroreceptor) regulation; SIADH and diabetes insipidus correlation
• Glucagon effects: glycogenolysis, gluconeogenesis, lipolysis, ketogenesis; cAMP/PKA signaling pathway; counter-regulatory hormone role

The directive 'enumerate' demands systematic listing with brief elaboration. Structure: (a) 10 marks—list 8-10 antihypertensive classes with CCB mechanism (20%); (b) 10 marks—Type IV hypersensitivity with tuberculin testing, then Salmonella diseases with Widal interpretation (20%); (c) 10 marks—four growth disturbances with atrophy mechanisms (20%); (d) 10 marks—diagnose tuberculous meningitis, identify Ziehl-Neelsen stain, describe meningeal gross pathology (20%); (e) 10 marks—enumerate blood group systems for identification and paternity (20%). Allocate equal time per part; use diagrams for pathways and gross pathology.

• (a) Enumerates ≥8 antihypertensive classes (ACEI, ARBs, CCBs, thiazides, loop diuretics, beta-blockers, alpha-blockers, vasodilators, centrally acting) with CCB mechanism: L-type calcium channel blockade in vascular smooth muscle, reduced peripheral resistance
• (b)(i) Type IV hypersensitivity: Th1 cell activation, IFN-γ release, macrophage activation, granuloma formation; tuberculin test: 48-72 hours, induration ≥10mm positive, Mantoux technique
• (b)(ii) Typhoidal: enteric fever; non-typhoidal: gastroenteritis, bacteremia; Widal test: O and H agglutinins, rising titer ≥1:160, anamnestic response limitation
• (c) Four growth disturbances: hypertrophy, hyperplasia, atrophy, metaplasia; atrophy mechanisms: decreased protein synthesis, increased protein degradation (ubiquitin-proteasome), autophagy, apoptosis, decreased growth factors
• (d) Diagnosis: tuberculous meningitis; stain: Ziehl-Neelsen (acid-fast bacilli, red rods against blue background); gross pathology: thick, opaque exudate at base of brain, tubercles on meninges, hydrocephalus
• (e) Blood group systems: ABO, Rh (D), MNSs, Kell, Duffy, Kidd, Lewis, P1PK, Hh, Xg; paternity testing: ABO, Rh, HLA, DNA fingerprinting; exclusion vs probability of paternity

The directive 'describe' demands detailed, structured exposition of morphology, mechanisms and clinical features across all sub-parts. Allocate ~40% time to part (a) [20 marks], ~20% to part (b) [10 marks], and ~40% to part (c) [20 marks]. Structure: brief introduction, then systematic coverage of (a)(i) oral cancer risk factors and morphology, (a)(ii) membranous GN etiology and morphology, (b) pharmacology tables for aspirin and cyclosporine, (c)(i) Plasmodium life cycle with RDT details, and (c)(ii) HHV enumeration with HSV lab diagnosis. Use diagrams for morphology and life cycles.

• Oral cancer: 5 risk factors (tobacco, alcohol, betel nut/areca nut, HPV-16, poor oral hygiene) and morphology (exophytic/ulcerative/verrucous, SCC features, field cancerization)
• Membranous GN: 5 causes (idiopathic, HBV, drugs like NSAIDs/penicillamine, SLE, malignancy) and morphology (diffuse GBM thickening, spike formation on silver stain, subepithelial deposits)
• Aspirin: therapeutic indications (antiplatelet, analgesic, antipyretic, anti-inflammatory), drug interactions (warfarin, methotrexate, ACE inhibitors), side effects (GI bleed, Reye syndrome, asthma)
• Cyclosporine: therapeutic indications (transplant rejection prophylaxis, autoimmune diseases), drug interactions (CYP3A4 inhibitors/inducers, nephrotoxic drugs), side effects (nephrotoxicity, hypertension, gingival hyperplasia, hepatotoxicity)
• Plasmodium falciparum asexual cycle: liver schizogony (exo-erythrocytic), RBC invasion, ring forms, trophozoites, schizonts, merozoites; RDT principle (HRP-2/pLDH detection), advantages (rapid, field applicable), disadvantages (cost, HRP-2 persistence, inability to quantify)
• HHV 1-8 with target cells (HSV-1/2: epithelial/neuronal; VZV: T cells/skin; EBV: B cells; CMV: multiple; HHV-6/7: T cells; HHV-8: endothelial/B cells); HSV lab diagnosis (Tzanck smear, viral culture, PCR, serology, antigen detection)

Begin with a brief introduction acknowledging the multi-system nature of the question spanning toxicology, hematology, cardiology, infectious disease and pharmacology. For part (a), allocate ~25% time covering poison classification with examples (corrosive, metallic, gaseous, organic), detailed Plumbism features (Burtonian line, wrist drop, anemia), and early diagnostic tests (urinary ALA, coproporphyrin, blood zinc protoporphyrin). For part (b)(i), spend ~20% on AML-M3 diagnosis, cytochemical stains (MPO, Sudan Black, NSE), and cytogenetics (t(15;17) favorable; -7, -5 unfavorable). For part (b)(ii), allocate ~20% describing rheumatic fever pathogenesis (molecular mimicry, Aschoff body) with microscopic findings. For part (c)(i), devote ~25% to complicated falciparum malaria management (IV artesunate, exchange transfusion criteria). For part (c)(ii), spend ~10% on insulin indications (DKA, HHS, Type 1 DM) and adverse effects (hypoglycemia, lipodystrophy). Conclude with integrative remarks on preventive aspects where relevant.

• Part (a): Classification of poisons by chemical nature (corrosive, metallic, gaseous, organic, vegetable, animal, mechanical) with Indian examples; Plumbism features including Burtonian line, lead colic, wrist drop, basophilic stippling, anemia; early diagnostic tests: urinary ALA, coproporphyrin, blood ZPP, serum lead levels
• Part (b)(i): Diagnosis of Acute Promyelocytic Leukemia (AML-M3) based on Auer rods and clinical presentation; cytochemical stains: MPO positive, Sudan Black positive, NSE negative; favorable cytogenetics: t(15;17)(q24;q21) PML-RARA, t(8;21); unfavorable: monosomy 7, monosomy 5, 11q23 abnormalities
• Part (b)(ii): Rheumatic heart disease pathogenesis: Group A streptococcal pharyngitis, molecular mimicry, autoimmune reaction; microscopic findings: Aschoff bodies with Anitschkow cells, fibrinoid necrosis, perivascular granulomatous inflammation
• Part (c)(i): Complicated P. falciparum malaria management: IV artesunate as first-line, quinine alternative, exchange transfusion criteria (parasitemia >10% or >5% with complications), supportive care, prevention of blackwater fever
• Part (c)(ii): Insulin therapeutic indications: Type 1 DM, DKA, HHS, gestational diabetes, perioperative hyperglycemia; adverse effects: hypoglycemia, weight gain, lipodystrophy, allergic reactions, insulin resistance

This multi-part descriptive question requires systematic coverage of four distinct areas: microbiology (20 marks), forensic medicine (20 marks), and pharmacology (10 marks). Allocate approximately 40% time to microbiology parts (a)(i)-(ii), 40% to forensic medicine (b)(i)-(ii), and 20% to pharmacology (c)(i)-(ii). Begin each sub-part with precise definitions where asked, followed by structured elaboration using bullet points or numbered lists for laboratory steps, legal sections, and mechanisms. Include labeled diagrams for Cryptococcus morphology, bullet markings, and DNA fingerprinting techniques. Conclude with public health relevance for infectious disease parts.

• Cryptococcus neoformans: India ink negative staining showing encapsulated budding yeast, narrow-based budding, urease positive; pathogenesis via inhalation → pulmonary focus → hematogenous spread to CNS in immunocompromised (HIV/AIDS)
• Meningococcaemia: definition as presence of N. meningitidis in blood with septicemia; CSF Gram stain, culture on chocolate agar, latex agglutination, PCR; vaccines: MenACWY (conjugate), MenB (Bexsero, Trumenba), Indian availability through UIP
• IPC definitions: Injury (Section 44), Hurt (Section 319), Grievous Hurt (Section 320 with eight clauses); secondary bullet markings: rifling impressions, striations, class vs individual characteristics
• Finger impressions: loop, whorl, arch (plain and tented); DNA fingerprinting: VNTR, STR analysis, Alec Jeffreys technique, forensic applications in paternity and criminal cases
• Potassium-sparing diuretics: spironolactone (aldosterone antagonist), amiloride/triamterene (ENaC blockers) - mechanism at collecting duct principal cells
• Zidovudine: NRTI for HIV, chain terminator, indications in PEP and PMTCT; adverse effects: myelosuppression, lactic acidosis, lipodystrophy, hepatotoxicity

The directive 'outline' demands a structured, systematic presentation of facts across five distinct clinical topics without elaborate discussion. Begin with a brief introduction acknowledging the breadth of topics (infectious disease, psychiatry, child health, immunization, dermatology), then address each sub-question in sequence with clear headings, bullet points for clinical features and management steps, and a concise conclusion emphasizing integrated healthcare delivery in the Indian context.

• Dengue: Distinguish DF (fever, myalgia, rash) from DHF (hemorrhagic manifestations, plasma leakage, shock) with WHO 2009 classification criteria
• Schizophrenia: Cover positive symptoms (hallucinations, delusions, disorganized speech/behavior) and negative symptoms (alogia, avolition, affective flattening) per DSM-5/ICD-10
• IMNCI: Full form (Integrated Management of Neonatal and Childhood Illnesses), objectives (reduce mortality, improve care quality), and 4 components (assess, classify, treat, counsel)
• Immunization: Complete UIP schedule including BCG, OPV, Hep-B at birth; Pentavalent, OPV, Rotavirus, IPV, PCV at 6/10/14 weeks; MR/MMR, DPT booster doses; special focus on Mission Indradhanush
• Lichen planus: Diagnosis from classic PPL (pruritic, polygonal, purple, planar papules), oral findings (Wickham striae, erosive lesions), and stepwise management (topical steroids, systemic agents for refractory cases)

The directive 'outline' demands a structured, systematic presentation of diagnostic reasoning, investigations, and management plans. Allocate approximately 40% of effort to part (a) given its 20 marks weightage, with 30% each to parts (b) and (c). Structure each case as: clinical presentation → diagnosis → investigations → management, ensuring crisp bullet points for investigations and tabular formats for CSF differentiation in (a)(iii).

• Part (a): Diagnosis of tubercular meningitis with cranial nerve involvement (CN VI palsy causing diplopia); CSF analysis showing lymphocytic pleocytosis, low glucose, high protein, and ADA levels; differentiation table of pyogenic (neutrophilic, low glucose), tubercular (lymphocytic, low glucose, high protein), and viral (lymphocytic, normal glucose) meningitis
• Part (a): ATT regimen (HRZE for 2 months, HR for 7-10 months) with corticosteroids for cerebral edema and raised ICT management; mention of DOTS strategy relevance in Indian context
• Part (b): Diagnosis of cyanotic spell/hypercyanotic spell in Tetralogy of Fallot (TOF) with differential of other cyanotic CHD; emergency management in knee-chest position, oxygen, morphine, IV fluids, sodium bicarbonate if acidotic, and beta-blockers
• Part (b): Classification of cyanotic CHD into: (1) increased pulmonary blood flow (TAPVC, TGA), (2) decreased pulmonary blood flow (TOF, tricuspid atresia), and (3) parallel circulation (single ventricle, truncus arteriosus)
• Part (c): Diagnosis of seborrheic dermatitis; sites including scalp, nasolabial folds, eyebrows, glabella, presternal area, interscapular region, and flexural areas
• Part (c): Role of Malassezia furfur (Pityrosporum ovale) in pathogenesis; treatment with ketoconazole shampoo, topical antifungals, mild topical corticosteroids, and calcineurin inhibitors for maintenance

The directive 'discuss' demands a comprehensive, analytical treatment across all five sub-parts. Allocate approximately 40% of time/words to part (a) given its 20 marks, 30% to part (c) for its integrated therapeutic discussion, and 30% to part (b) with its mechanistic focus. Structure as: brief introduction → systematic coverage of (a) CRF with Indian CKD burden context → (b) neonatal jaundice with NICE/Indian Academy of Pediatrics alignment → (c) psoriasis with nail-specific details → concluding synthesis on chronic disease management.

• Part (a): CRF aetiology—diabetic nephropathy, HTN, CGN, obstructive uropathy, CIN; CKD staging (GFR-based); uremic manifestations; dialysis modalities and transplant criteria
• Part (b)(i): Unconjugated hyperbilirubinemia causes—physiological, breast milk jaundice, G6PD deficiency (common in India), ABO/Rh incompatibility, spherocytosis, hypothyroidism, Crigler-Najjar
• Part (b)(ii-iii): Phototherapy mechanism—photoisomerization of unconjugated bilirubin to lumirubin and configurational isomers; complications—bronze baby syndrome, dehydration, retinal damage, skin rash, temperature instability
• Part (c)(i): Nail findings in psoriasis—oil drop sign, pitting, onycholysis, subungual hyperkeratosis, splinter hemorrhages, nail bed salmon patch
• Part (c)(ii): Topical therapy—corticosteroids, vitamin D analogues (calcipotriol), dithranol, coal tar; Systemic—methotrexate, cyclosporine, acitretin, biologics (anti-TNF, IL-17/23 inhibitors); PASI scoring relevance

The directive 'outline' for part (a)(iv) and the enumeration demands in parts (b) and (c) require structured, hierarchical presentation. Allocate approximately 40% of time/space to part (a) given its 20 marks with clinical reasoning depth, 40% to part (b) for precise WHO criteria and ten-step protocol, and 20% to part (c) for concise radiological differentials. Begin each sub-part with clear headings, use bullet points for criteria and steps, and conclude with brief clinical relevance statements.

• Part (a): Diagnosis of bronchial asthma with seasonal pattern; confirmation via spirometry with reversibility (FEV1 improvement ≥12% and ≥200ml post-bronchodilator), peak expiratory flow variability; clinical features including episodic dyspnea, wheeze, chest tightness, nocturnal symptoms, triggers; stepwise GINA management from Step 1 (SABA PRN) to Step 5 (high-dose ICS-LABA + add-ons)
• Part (b)(i): WHO criteria for SAM—weight-for-height/length Z-score <-3 SD OR mid-upper arm circumference (MUAC) <11.5 cm OR bilateral pitting edema (nutritional edema); age 6-59 months
• Part (b)(ii): Facility-based admission criteria—complicated SAM (edema++, severe illness, anorexia, failed outpatient care, HIV/infant <6 months/other danger signs) per WHO/Indian Academy of Pediatrics guidelines
• Part (b)(iii): Ten steps—treat/prevent hypoglycemia, hypothermia, dehydration, electrolyte imbalance, infection, micronutrient deficiencies; initiate cautious feeding, achieve catch-up growth, provide sensory stimulation, prepare for follow-up (WHO protocol)
• Part (c): X-ray in acute abdomen—erect chest for free air under diaphragm (perforation), supine abdomen for dilated bowel loops/valvulae conniventes/coffee bean sign (volvulus), air-fluid levels on erect abdomen (obstruction), sentinel loop (pancreatitis), psoas shadow obliteration (retroperitoneal pathology), calcifications (renal/ureteric stones, chronic pancreatitis), loss of flank stripe (ascites)

The directive 'describe' demands systematic, detailed exposition of clinical features, investigations, and management across all sub-parts. Allocate approximately 20% (10 marks) to each sub-part equally. Structure: begin with (a) dysphagia workup emphasizing malignancy exclusion; (b) emergency variceal bleed protocol with pharmacological and endoscopic steps; (c) prolapse risk factors then comprehensive surgical management for complex procidentia; (d) definition followed by anatomically-organized causes of chronic pelvic pain; (e) JSSK entitlements with specific free services and transport provisions. Use standard headings, prioritize recent Indian guidelines (MOHFW, ICMR), and conclude each part with patient-centered outcomes.

• (a) Progressive dysphagia with weight loss: prioritize esophageal malignancy; outline stepwise investigation—barium swallow, upper GI endoscopy with biopsy, CT chest-abdomen for staging, PET-CT if available; mention differential (achalasia, peptic stricture, external compression)
• (b) Severe hematemesis in portal hypertension: immediate resuscitation (IV access, fluids, blood products), pharmacotherapy (terlipressin/octreotide, antibiotics), endoscopic band ligation/sclerotherapy as definitive, balloon tamponade as bridge, TIPS for refractory cases; mention Child-Pugh stratification
• (c)(i) Pelvic organ prolapse risk factors: parity/vaginal delivery, advancing age, menopause/estrogen deficiency, chronic raised intra-abdominal pressure (cough, constipation, heavy lifting), connective tissue disorders
• (c)(ii) Complex procidentia management: conservative (pessary, pelvic floor exercises) vs surgical—vaginal hysterectomy with pelvic floor repair (anterior/posterior colporrhaphy), McCall culdoplasty, sacrospinous fixation, or abdominal/laparoscopic sacrocolpopexy based on fitness
• (d) Chronic pelvic pain: define as non-cyclic pain ≥6 months; causes—gynecological (endometriosis, adenomyosis, chronic PID, ovarian remnant), urological (interstitial cystitis), gastrointestinal (IBS, IBD), musculoskeletal (pelvic floor tension myalgia), psychological
• (e) JSSK entitlements: free ANC, delivery (including C-section), postnatal care; free diagnostics, drugs, consumables; free transport from home to facility and back; free treatment of sick neonates up to 30 days including transport between facilities

The primary directive is 'discuss' for PPH management (10 marks), with secondary directives 'enumerate' for causes and signs, 'outline' for diagnostic workup, and 'state' for management and NRHM initiatives. Allocate approximately 40% of time/words to part (a) PPH (20 marks), 30% to part (b) peripheral arterial disease (15 marks), and 30% to part (c) NRHM (15 marks). Structure with brief introductions for each part, systematic enumeration followed by explanatory discussion where demanded, and conclude with integrated takeaways on emergency preparedness and rural healthcare strengthening.

• Part (a)(i): Enumerate 4Ts of PPH causes (Tone-uterine atony, Trauma, Tissue-retained placenta, Thrombin-coagulopathy) plus additional causes like uterine inversion, lacerations
• Part (a)(ii): Discuss medical management (uterotonics: oxytocin, misoprostol, ergometrine, carboprost), mechanical methods (uterine massage, bimanual compression), surgical interventions (B-Lynch suture, uterine artery ligation, hysterectomy), and WHO/FIGO guidelines
• Part (b)(i): Enumerate 6Ps of acute ischaemia (Pain, Pallor, Pulselessness, Paralysis, Paraesthesia, Poikilothermia) plus Rutherford classification stages, chronic limb threatening ischaemia signs
• Part (b)(ii-iii): Outline ABI measurement, duplex ultrasound, CTA/MRA angiography; state management including risk factor modification, antiplatelets (aspirin, clopidogrel), statins, cilostazol, endovascular interventions (angioplasty, stenting), and bypass surgery
• Part (c): State ASHA workers, Janani Suraksha Yojana, Janani Shishu Suraksha Karyakram, Mobile Medical Units, Rogi Kalyan Samitis, Indian Public Health Standards (IPHS), and Accredited Social Health Activist (ASHA) roles in rural healthcare infrastructure

The directive 'enumerate' demands systematic listing with brief elaboration. Allocate approximately 40% effort to part (a) radiology (20 marks), 30% to part (b) biochemistry (15 marks), and 30% to part (c) gynecology (15 marks). Structure as: brief introduction → systematic enumeration for each sub-part with 1-2 lines per point → concluding summary emphasizing clinical integration across radiology, biochemistry, and public health.

• Part (a)(i): Causes of radio-opacities on plain AXR—renal/ureteric calculi, calcified lymph nodes, vascular calcifications, gallstones (if calcified), foreign bodies, calcified masses
• Part (a)(ii)-(iv): Causes of adult hydronephrosis (obstructive vs non-obstructive), stepwise investigation protocol (USG → CT-IVU → nuclear renogram), and PUJ obstruction management (endopyelotomy vs laparoscopic pyeloplasty vs open Anderson-Hynes)
• Part (b)(i)-(ii): Essential amino acids definition and six examples (PVT TIM HALL mnemonic), biological completeness criteria (all essential amino acids in adequate proportion), supplementary action with Indian dietary example (cereal-pulse combination like rice-dal)
• Part (c)(i)-(iii): Cervical cancer screening methods (Pap smear, VIA, HPV DNA testing), risk factors (HPV 16/18, early marriage, multiparity, smoking, HIV), preventive strategies (HPV vaccination, screening, safe sex practices, WHO 90-70-90 targets)
• Integration point: Link PUJ obstruction management to renal preservation principles; connect protein supplementation to Indian public health programs (ICDS, midday meal); tie cervical cancer prevention to National Cancer Control Programme

Begin with the directive 'state' for part (a), which demands precise factual recall of the National Framework for Malaria Elimination. Allocate approximately 40% of time/words to part (a) given its 20 marks, covering vision, goals, objectives, milestones (2024, 2027, 2030) and broad strategies. For part (b) (30% allocation), apply 'how' for grading anaemia, 'list' for complications, and 'outline' for labour management. For part (c) (30% allocation), use 'enumerate' for splenectomy indications and 'mention' for OPSI pathogenesis and prophylaxis. Structure as: (a) comprehensive framework details → (b) obstetric anaemia progression from diagnosis to emergency management → (c) surgical indications leading to immunological consequences.

• Part (a): Vision of malaria-free India; goals of elimination in low-burden states by 2024, all states by 2027, maintenance by 2030; objectives of reducing API, mortality, indigenous cases; milestones (2024: zero indigenous in category 1 states, 2027: zero indigenous nationwide, 2030: prevention of re-establishment); strategies including case-based surveillance, vector control, cross-border coordination
• Part (b)(i): WHO haemoglobin grading in pregnancy—mild (10.0-10.9 g/dL), moderate (7.0-9.9 g/dL), severe (<7.0 g/dL); physiological dilution consideration
• Part (b)(ii): Maternal complications (heart failure, infection, PPH, eclampsia, maternal death); fetal complications (IUGR, preterm labour, low birth weight, perinatal mortality)
• Part (b)(iii): Labour management of severe anaemia—oxygen, IV access, blood transfusion criteria (Hb <5 g/dL or 5-7 g/dL with complications), active management of third stage, ergometrine avoidance, iron/folate supplementation, cardiorespiratory monitoring
• Part (c)(i): Therapeutic splenectomy indications—hereditary spherocytosis, ITP refractory, autoimmune haemolytic anaemia, thalassaemia major, hypersplenism, trauma, lymphoproliferative disorders, staging laparotomy for Hodgkin lymphoma
• Part (c)(ii): OPSI aetiopathogenesis—impaired opsonization, decreased IgM/IgG production, defective clearance of encapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis); fulminant sepsis within 2 years post-splenectomy; prophylaxis—pneumococcal, meningococcal, Hib vaccines, daily penicillin prophylaxis, patient education, emergency standby antibiotics